AbbVie Inc. Depreciation & Amortization

Depreciation & Amortization of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization for the quarter ending December 30, 2019 was $509 Million (a 1.19% increase compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization increased by 1.19%
  • Annual Depreciation & Amortization for 2019 was $2.02 Billion (a 14.28% increase from previous year)
  • Annual Depreciation & Amortization for 2018 was $1.77 Billion (a 17.59% increase from previous year)
  • Annual Depreciation & Amortization for 2017 was $1.5 Billion (a 26.24% increase from previous year)
  • Twelve month Depreciation & Amortization ending December 30, 2019 was $2.02 Billion (a 3.44% increase compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization increased by 10.64% year-over-year
Trailing Depreciation & Amortization for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$2.02 Billion $1.95 Billion $1.88 Billion $1.82 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization of AbbVie Inc.

Most recent Depreciation & Amortizationof ABBV including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization of AbbVie Inc.

AbbVie Inc. Depreciation & Amortization for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $509.0 $503.0 $502.0 $503.0 $2,017.0
2018 $442.0 $435.0 $443.0 $445.0 $1,765.0
2017 $369.0 $379.0 $379.0 $374.0 $1,501.0
2016 $328.0 $304.0 $289.0 $268.0 $1,189.0
2015 $261.0 $227.0 $190.0 $158.0 $836.0
2014 $193.0 $192.0 $202.0 $199.0 $786.0
2013 $200.0 $234.0 $236.0 $227.0 $897.0
2012 $309.0 $227.0 $295.0 $319.0 $1,150.0
2011 $324.87 $315.23 $317.61 $314.48 $1,272.0
2010 $1,184.36 $1,184.0
2009 $697.49 $697.49

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.